中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 1 Emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu in Her2/neu-overexpressing.

Slides:

Advertisements

Similar presentations

Modulation of the Cellular Phenotype in Human Colon Adenocarcinoma Cells by Folic Acid and Polyamine Pools Nathan W. Sweeney, Julie A. Buckmeier, Christina.

Advertisements

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases.

Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.

Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.

Targeted Therapy: A Giant Step Forward

MAHNAZ JANGHORBAN CANB610 3/8/2012 ETV1 and GIST Pathogenesis Gastrointestinal stromal tumors (GISTs) arise from the interstitial cells of Cajal (ICC)

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Co-supervisor: Prof Richard Lock

RNA-binding Protein Insulin-like Growth Factor mRNA-binding Protein 3 (IMP-3) Promotes Cell Survival via Insulin-like Growth Factor II Signaling after.

Introduction The effects of HER2 gene and receptor overexpression on breast cancer. Prognosis and treatment of HER2+ breast cancer. (See figure 1)

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER Trends in the survival of patients with nasopharyngeal carcinoma in Sihui city, Guangdong province,

Huidi Liu, M.D. & Ph.D Genomics Research Centre Harbin Medical University, China Reduced expression of SOX7 in ovarian cancer: a novel.

Antibody and prodrug therapy of cancer

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

CLU inhibition using OGX-011 synergistically enhances Zol activity in osteosarcoma François Lamoureux, Marc Baud’huin, Benjamin Ory, Martin E. Gleave,

RA190 Small Molecule Proteasome Inhibitor for Cancer Therapy.

Functional interactions between calmodulin and estrogen receptor-α

Heat Shock Protein 90 (HSP90) is over-expressed in p16 negative oropharyngeal squamous cell carcinoma and its inhibition in vitro potentiates the effects.

Ribosomal Dysfunction Results in an Immunologic Susceptibility to Lung Cancer Stephanie Chang MD, Ryuji Higashikubo PhD, Saeed Arefanian MD, Andrew Gelman.

Inhibition of PDCD6 Induces Cell Proliferation and Reduces Apoptosis in Human Epithelial Ovarian Cancer Cells Yan Huang, Xiaohua Wu Department of Gynecology,

EXPRESSION OF HER-2 CORRELATED PROTEINS IN ILEAL CARCINOIDS Azzoni C., Giordano G., Bottarelli L., Tamburini E., D’Adda T., Pizzi S., Rindi G., Bordi C.

T argeting S phingosine K inase 1 and A poptosis by M etformin to D ecrease T umor R esistance to A driamycin By Dr. Ahmed Mohamed Kabel Pharmacology.

VR-23, a New Anticancer Drug Developed in Northern Ontario Hai-Yen Vu, PhD and Hoyun Lee, PhD.

Metabolic Syndrome: Focused on AMPK as Molecular Target for Metabolic Syndrome Bayu Lestari.

Targeting EZH2 for cancer therapy

Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Angel A. Rodriguez, Anne C. Pavlick, Tao Wang, Susan G. Hilsenbeck,

Dual Inhibition of Cdc7 and Cdk9 by PHA Suppresses Hepatocarcinoma Synergistically with 5-FU Xi Chen, MD, PhD Associate Professor, Zhejiang University.

Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.

第三章 Survivin siRNA nano particles are capable of inhibiting liver cancer cell growth both in vitro and in vivo Suoqin Tang,MD, Kuiyao Qu,MD, Yi Zhang,MD.

Lactate dehydrogenase is crucial for tumor associated macrophage protection of multiple myeloma cells against chemotherapy Carolyn Stierhoff, Enguang Bi,

Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.

School of Life Sciences of USTC 2005 Her2 Signalling Pathway & Anti-her2 Therapy Mechanism ——Wang Peng.

Kui Wang May 6th, 2017.

Biological activity of novel synthetic tylophorine analogs in MCF-7 breast cancer cells Przemysław Czajkowski 1, Edyta Andrulewicz 1, Anna Bielawska.

Leila Kokabee*, Xianhui Wang, Cheryl Eifert, Douglas S. Conklin

Cell Physiol Biochem 2017;42:2582– DOI: /

Necitumumab Drugbank ID :DB09559 Molecular Weight (Daltons) :144800

Objectives Introduction Ags expressed by cancer cells

Novel Transcription Factor Inhibitor as Treatment for Epithelial Cell Cancers John Bushweller, Department of Molecular Physiology and Biological Physics,

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the function of multiple ATP-binding cassette transporters Yanjun Mi, Liwu Fu State Key.

Targeting p53 for Oncology Drug Discovery

Fig. 1 Increased MIR155HG expression correlates with glioma grade and mesenchymal transition and confers a poor prognosis in GBM patients. (A) The level.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2 Cell.

A new therapeutic antibody masks ErbB2 to its partners

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Table 1. Scientific findings of previously published work on Graviola

Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.

Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma Jia Wang, Tong Yang, Gaofeng Xu, Hao Liu, Chunying.

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation Lily Mahapatra, Neal Andruska, Chengjian Mao,

Figure 1 A schematic representation of the HER2 signalling pathway

Marissa V. Powers, Paul A. Clarke, Paul Workman Cancer Cell

Michèle Algarté-Génin, Olivier Cussenot, Pierre Costa European Urology

Marissa V. Powers, Paul A. Clarke, Paul Workman Cancer Cell

Figure 5 The mechanism underlying epithelial-to-mesenchymal

A new therapeutic antibody masks ErbB2 to its partners

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Jenny L. Weon, Seung Wook Yang, Patrick Ryan Potts Molecular Cell

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

subunits of hemoglobin in the presence and absence of heme.

Potential model of HMQ1611 inhibiting breast cancer cell proliferation

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

Presentation transcript:

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 1 Emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu in Her2/neu-overexpressing cancer cells Li-sheng Zheng, Yan-yan Yan, Li-wu Fu Cancer Center, Sun Yat-sen University

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 2  Overexpression of HER2/neu is common in multiple malignancies, including breast, ovarian, lung and prostate cancer, etc.  Clinical studies have demonstrated that elevated HER2/neu expression correlates with poor prognosis in multiple malignancies  During the last decade, HER2/neu has been targeted in order to develop novel anticancer drugs Trastuzumab (Herceptin®) Lapatinib (Tykerb) efficacy and long-term use in patients are quite limited due to resistance to these inhibitors or severe side effects Background

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 3  Anthraquinone derivative  Active ingredient of various Chinese herbs including rhubarb, Polygonum cuspidatum  Anti-bacterial, anti-inflammatory, anti-tumor Emodin Structure of emodin Background  Block auto- or trans-phosphorylation of HER2/neu  Increases the susceptibility of HER2/neu overexpressing cancer cells to standard cytotoxic therapeutic agents

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 4  anticancer activity not obvious  side effects such as cardiac toxicity  We and Professor Lian-quan Gu group (School of Chemistry and Chemical Engineering, Sun Yat-sen University) modified structure of emodin and synthesized a series of emodin anthraquinone derivatives Background Structure of emodin AMAD

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 5 AMAD shows potent anticancer effect on breast cancer and lung adenocarcinoma cell lines

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 6 AMAD inhibits the growth of human non-small cell lung carcinoma H460 cell xenografts in nude mice

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 7 AMAD down-regulates Her2/neu protein expression

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 8 AMAD inhibits Her2/neu downstream signaling pathways

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 9 AMAD increses Her2/neu protein instability

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 10 AMAD induces polyubiquitination of HER2/neu

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 11 AMAD depletes HER2/neu by proteasomal degradation

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 12 AMAD inhibited Her2/neu binding to Hsp90

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 13 Knockdown Her2/neu by siRNA induces growth inhibition

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 14 Combination of AMAD and siRNA against Her2 synergistically induces apoptosis

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 15 Combination of AMAD and siRNA against Her2 further promotes HER2/neu degradation and inhibites downstream signaling pathways

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 16 Discussion Apigenin and Geldanamycin can induce HER2 protein degradation by ubiquitin-proteasome pathway  Downregulation of HER2 by AMAD is dependent of Her2 protein stability but not mRNA level  Dissociation of Her2/Hsp90 heterocomplex by AMAD may be correlated with promoted proteasomal degradation of Her2 protein  HER2 specific: AMAD does not decrease the expression of Her1 protein

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 17  AMAD exerts potent cytotoxic effects on MDA-MB-453 and Calu-3 cells.  AMAD inhibits the proliferation via MAPK and PI(3)K/Akt pathway signaling.  AMAD targets HER2/neu to ubiquitinylation-dependent proteasomal degradation.  Combined AMAD with siRNA against HER2/neu further promotes Her2/neu degradation, induces apoptosis and inhibits the proliferation. Conclusions

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 18 谢谢 !